Bethesda, Maryland – In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. Researchers at the National Cancer Institute (NCI), part...
Latest News
High-risk research into neglected diseases, which can often fail at the first hurdle, may be made safer as a result of a new programme. The Therapeutics for Rare and Neglected Diseases (TRND) Programme will support preclinical research in which candidate drugs are tested in cells or animals — one of...
Bethesda, MD – Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies—a human broadly neutralizing antibody and two antibodies isolated from previously vaccinated monkeys—target the fusion peptide, a site...
Niigata, Japan –Dialysis patients often develop dialysis-related amyloidosis and exhibit bone and joint disorders that impair their activity of daily living. Blood purification devices consisting of hexadecyl-immobilized cellulose beads aimed at removing the precursor protein, β2– microglobulin (β2-m), are used in the treatment of dialysis-related amyloidosis. Dr. Yamamoto et al....
MISSISSAUGA – YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced...
Denver, CO – Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to a study published today in The New England Journal of Medicine. The results of the non-inferiority study were presented at...
SANTA ANA, Calif. — NKGen Biotech Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has received a No Objection Letter (“NOL”) from Health Canada for its Clinical Trial Application (“CTA”) for a Phase...
SANTA ANA, Calif. — NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial evaluating SNK01, a cryopreserved autologous, non-genetically modified NK cell therapy...
STANS, Switzerland – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces new study data which support the mechanism of action for mazindol, the active...
STANS, Switzerland – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into a License Agreement (the “Agreement”) with Novartis Pharma...